Medtronic Neuromodulation
7000 Central Ave., N.E., Minneapolis, MN, US
Registered product codes
26 product codes
Recent MDR events
58,987 on file
- Sensia IPGJul 31, 2026Malfunction2182207-2026-02120
- Implantable NeurostimulatorJul 31, 2026Malfunction2182207-2026-02121
- PerceptJul 31, 2026Malfunction2182207-2026-02122
- Implantable NeurostimulatorJul 31, 2026Malfunction2182207-2026-02123
- ACTIVAJul 31, 2026Malfunction2182207-2026-02124
- SURESCANJul 31, 2026Injury2182207-2026-02125
- ACTIVAJul 31, 2026Malfunction2182207-2026-02126
- Implantable NeurostimulatorJul 31, 2026Injury2182207-2026-02127
- SynchroMed IIIJul 31, 2026Malfunction2182207-2026-02128
- INTELLISJul 31, 2026Injury2182207-2026-02113
Recalls
176 on file
- Open, ClassifiedMay 28, 2026
A limited number of Pocket Adaptor Kits, Model 64001 and 64002, are labeled with incorrect Use-By-Dates.
View FDA record ↗ - Open, ClassifiedMay 28, 2026
A limited number of Pocket Adaptor Kits, Model 64001 and 64002, are labeled with incorrect Use-By-Dates.
View FDA record ↗ - Open, ClassifiedMay 14, 2026
Software issue: When programming the SynchroMed Pump with the A810 CP App in Flex Infusion Mode, the infusion steps should automatically be arranged in consecutive order, from earliest to latest. However, in rare cases, the steps may be displayed out of order. If this occurs, the programmed Flex Infusion schedule will not be delivered at the intended time, if at all.
View FDA record ↗ - Open, ClassifiedJan 9, 2026
Complaints received that Vanta A71200 CP App does not function as intended during use. There is a potential for prolonged or postponed surgical procedure.
View FDA record ↗ - Open, ClassifiedDec 23, 2025
Software issue where a Device Reset message displayed on the app was unable to be cleared. In rare cases, this resulted in an inability to resume therapy, and the patient experienced a recurrence of underlying pain symptoms. Resolution would require surgical replacement of the INS.
View FDA record ↗ - Open, ClassifiedApr 30, 2025
Evaluation handsets may not be able to communicate with the neurostimulator due to handsets having a faster processing speed than prior handsets. An inability to connect may cause the therapy to stop being delivered and a system error will be displayed. Patient may experience return of underlying disease symptoms (e.g. overactive bladder, urinary retention, or fecal incontinence) based on their response to stimulation during the evaluation period.
View FDA record ↗ - Open, ClassifiedApr 8, 2025
There is a software issue that can permanently disable communication with an implantable neurostimulator (INS) when a specific intraoperative programming sequence is used.
View FDA record ↗ - Open, ClassifiedApr 1, 2025
Product complaints were received describing the A820 myPTM app taking longer than expected for patients to interact with their implantable pump.
View FDA record ↗ - Open, ClassifiedDec 27, 2024
Software issues were identified in application version 2.x.
View FDA record ↗ - Open, ClassifiedDec 27, 2024
Software issues were identified in application version 2.x.
View FDA record ↗
Compliance history
Matched by FEI 2182207.
FDA inspections
0 on file
No inspections on file for this FEI number.
Inspection citations
0 on file
No citations on file for this FEI number.
Compliance actions
0 on file
No warning letters or injunctions on file for this FEI number.
Import refusals
0 on file
No import refusals on file for this FEI number.